Obserwuj
John Cook
John Cook
Singular Value Consulting
Zweryfikowany adres z singularvalueconsulting.com - Strona główna
Tytuł
Cytowane przez
Cytowane przez
Rok
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
RECOVERY Collaborative Group
Lancet (London, England) 397 (10285), 1637, 2021
15162021
Dose-finding based on efficacy–toxicity trade-offs
PF Thall, JD Cook
Biometrics 60 (3), 684-693, 2004
5452004
The clinical and cost-effectiveness of total versus partial knee replacement in patients with medial compartment osteoarthritis (TOPKAT): 5-year outcomes of a randomised …
DJ Beard, LJ Davies, JA Cook, G MacLennan, A Price, S Kent, J Hudson, ...
The Lancet 394 (10200), 746-756, 2019
2382019
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis
O Abani, A Abbas, F Abbas, J Abbas, K Abbas, M Abbas, S Abbasi, ...
The Lancet 400 (10349), 359-368, 2022
2082022
Adaptive dose selection using efficacy-toxicity trade-offs: illustrations and practical considerations
PF Thall, JD Cook, EH Estey
Journal of Biopharmaceutical Statistics 16 (5), 623-638, 2006
762006
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
O Abani, A Abbas, F Abbas, M Abbas, S Abbasi, H Abbass, A Abbott, ...
The Lancet 399 (10325), 665-676, 2022
752022
Breast cancer imaging with radiolabelled peptide from complementarity-determining region of antitumour antibody
GB Sivolapenko, V Douli, G Sirmalis, E Merkouri, K Konstantinides, ...
The Lancet 346 (8991-8992), 1662-1666, 1995
651995
Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias …
M De Lima, RE Champlin, PF Thall, X Wang, TG Martin, JD Cook, ...
Leukemia 22 (2), 258-264, 2008
592008
Bayesian design of single-arm phase II clinical trials with continuous monitoring
VE Johnson, JD Cook
Clinical Trials 6 (3), 217-226, 2009
502009
A case for robust Bayesian priors with applications to clinical trials
JD Cook, JA Fúquene, LR Pericchi
472009
Accounting for patient heterogeneity in phase II clinical trials
JK Wathen, PF Thall, JD Cook, EH Estey
Statistics in medicine 27 (15), 2802-2815, 2008
472008
Basic properties of the soft maximum
JD Cook
bepress, 2011
452011
Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
O Abani, A Abbas, F Abbas, M Abbas, S Abbasi, H Abbass, A Abbott, ...
The Lancet 399 (10320), 143-151, 2022
432022
Dose–schedule finding in phase I/II clinical trials using a Bayesian isotonic transformation
Y Li, BN Bekele, Y Ji, JD Cook
Statistics in medicine 27 (24), 4895-4913, 2008
412008
The use of patient-reported outcome measures to guide referral for hip and knee arthroplasty: part 1: the development of an evidence-based model linking preoperative score to …
AJ Price, S Kang, JA Cook, H Dakin, A Blom, N Arden, R Fitzpatrick, ...
The Bone & Joint Journal 102 (7), 941-949, 2020
392020
Determining distribution parameters from quantiles
JD Cook
bepress, 2010
322010
Notes on the negative binomial distribution
JD Cook
Unknow, October 28, 2009, 2009
302009
Exact calculation of beta inequalities
J Cook
Houston: University of Texas, MD Anderson Cancer Center, 2005
292005
Practical model-based dose finding in early-phase clinical trials: optimizing tissue plasminogen activator dose for treatment of ischemic stroke in children
HT Whelan, JD Cook, CM Amlie-Lefond, CA Hovinga, AK Chan, ...
Stroke 39 (9), 2627-2636, 2008
252008
The development of APT methodology in the application and derivation of geosynthetic benefits in roadway design
J Cook, M Dobie, D Blackman
The Roles of Accelerated Pavement Testing in Pavement Sustainability …, 2016
232016
Nie można teraz wykonać tej operacji. Spróbuj ponownie później.
Prace 1–20